Initial comparative response to peak pions and x-rays of normal skin and underlying tissue surrounding superficial metastatic nodules

Kligerman, M.M.; West, Gary; Dicello, J.F.; Sternhagen, CJ; Barnes, JE; Rk, Loeffler; Dobrowolski, F.; Bradbury, J.; Lane, TF; Petersen, DF; Ea, Knapp

doi:10.2214/ajr.126.2.261

Cited by 22 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Castro et al reported radioresponsiveness to a mixed beam of neutrons and photons from an implant of californium. Kligerman et al observed that cutaneous nodules of malignant melanomas regressed at least as rapidly with pi meson therapy as with X rays. Radiosensitizing drugs, such as misonidazole, which act as oxygen substitutes, are currently being tested and offer some promise of achieving better results with conventional equipment…”

Section: The Future Of Radiotherapy In the Management Of Malignant Mementioning

confidence: 99%

Present Role and Future Prospects for Radiotherapy in the Management of Malignant Melanomas

Cooper¹,

Kopf²,

Bart³

1979

The Journal of Dermatologic Surgery and Oncology

View full text Add to dashboard Cite

Malignant melanomas are not very radiosensitive neoplasms. Therefore, the prime management of such lesions is surgical. However, there are certain circumstances in which radiation therapy has been used and should be considered as useful. This article provides an overview of the literature on radiotherapy of primary and metastatic malignant melanomas in man. In addition, some unconventional methods like the use of radiation sensitizers, oxygen-independent radiation therapy, radiation combined with hyperbaric oxygen, and high-dose-perfraction irradiation are discussed. The beneficial responses to radiation that have been reported in the literature and that we have personally observed suggest that a prospective study to determine the proper role of radiation therapy in the management of all forms and stages of malignant melanomas is warranted.

show abstract

Section: The Future Of Radiotherapy In the Management Of Malignant Mementioning

confidence: 99%

Present Role and Future Prospects for Radiotherapy in the Management of Malignant Melanomas

Cooper¹,

Kopf²,

Bart³

1979

The Journal of Dermatologic Surgery and Oncology

View full text Add to dashboard Cite

show abstract

“…N EGATIVE pions were first used to irradiate tumors in patients on October 21, 1974 at the Meson Physics Facility at Los Alamos, New Mexico (1). Since these first irradiations of tumor nodules, about 40 patients with superficial and deep-lying tumors have been treated with the therapeutic pion beam.…”

mentioning

confidence: 99%

“…This improvement has been made possible by the increase in the primary proton current from 10 #lA to the present current of 300 #lAo Smith et al (2,3) have studied the dosimetry of the beams and the treatment planning. On the clinical side, Kligerman et al (1,4) have obtained information on the comparative response of human tumors to the pion peak and to x rays. Although much work lies ahead, a good beginning has been made for the study of pion treatment of human neoplasms.…”

mentioning

confidence: 99%

The Three Dose Components of a Negative Pion Beam and Their Role in Pion Radiotherapy

Richman¹,

Rodriguez²,

Malcom³

et al. 1978

Radiology

View full text Add to dashboard Cite

A new method has been developed for analyzing therapeutic negative pion beams into three LET (linear energy transfer) dose components inherent in such a beam. The technique utilizes thin silicon detectors to obtain pulse height spectra produced by the various particles in the beam traversing the detectors. It is shown that a low LET group is correlated with the incoming pions, muons and electrons; a medium LET group corresponds to protons, deuterons, tritons, and high energy alpha particles; and a high LET group is due to low energy alpha particles, 3He and recoil particles. Several beams used clinically have been studied.

show abstract

Particle radiation therapy.Current status and future potential

Parker¹

1977

Cancer

View full text Add to dashboard Cite

Radiation therapy with "heavy" particles offers potential biological and physical advantages compared to irradiation with low LET photons. Clinical studies are in progress with proton beams, which have dosimetric advantages, and fast neutron beams, which have potential biologic advantages. Clinical studies with negative pi mesons and heavy nuclei, which have combined dosimetric and biologic advantages are about to start.

show abstract

Initial comparative response to peak pions and x-rays of normal skin and underlying tissue surrounding superficial metastatic nodules

Cited by 22 publications

References 7 publications

Present Role and Future Prospects for Radiotherapy in the Management of Malignant Melanomas

Present Role and Future Prospects for Radiotherapy in the Management of Malignant Melanomas

The Three Dose Components of a Negative Pion Beam and Their Role in Pion Radiotherapy

Particle radiation therapy.Current status and future potential

Contact Info

Product

Resources

About